<![CDATA[Press Release Submission and Distribution Services | Press Release Power]]> en Tue, 07 Apr 2026 13:52:53 +0600 <![CDATA[Catherine Chuchylina: our solutions help to save lives giving access to remote diagnostic and treatment]]>

— Catherine, SK-Telemed GmbH specializes in telehealth, please share more information about it.


SK-Telemed is a digital healthcare provider, we specialize in development, implementation and support of our telehealth products around the world.


Nowadays, the main concentration of SK-Telemed is development and implementation of telehealth and IoT-solutions for private and public healthcare areas. Our cutting edge IT-products facilitate remote diagnostics, improve patients’ remote health monitoring, provide  doctor to patient communication and virtual care during the pandemic.  SK-Telemed is certificated by ISO 9001:2015 and 13485:2016. 


— Which countries do you work with?

Currently, we have 15 distributors. Among them: Austria, Poland, Ukraine, Brazil, Romania, Algeria, Senegal, Chile, Costa Rica, Guatemala, Kazakhstan, Egypt, Saudi Arabia, Ivory Coast, Zimbabwe, Portugal and the list is growing. Our team also is growing and supporting  our distributors in all countries in different time zones.


— What are the global challenges facing SK-Telemed and other IT solution providers? 

During 2020 and for now the world is facing COVID-19 pandemic. It is a golden age and multiplies the growth of demand for telehealth and telemedicine. Government public health programs and projects, dozens of new companies, online mode for thousands of patients and doctors, new easier rules for registrations and import. On the other side are new blockages and restrictions, lack of mobility between countries

and even cities.


— How did pandemic influence on the telehealth industry in the world?

In the focus are digital solutions for remote diagnostics, monitoring, treatment, communication. Everything is going online and healthcare sector also - especially during COVID-19 pandemic, when the possibility of remote diagnostic and treatment is a must to prevent spreading of infection.


As, for example, in 2020, during MEDICA Virtual Edition and other online events we saw a huge interest in digital tools for remote diagnostics, treatment and communication, as well as telehealth technologies — store-and-forward, telemonitoring, telemedicine, and mhealth. 


SK-Telemed headed the top list of companies in the Telemedicine category on the MEDICA2020. 


Thus, in response to the COVID-19 challenges,  SK-Telemed have the flagman products — Show2Doc (telemonitoring and communication platform) and IDIS2GO (telehealth medical diagnostic system).


— Which telehealth products are highly-demanded now?

Telehealth medical diagnostic system IDIS2GO is 100% fits for remote diagnostic in any patient location. It has been successfully integrated into public health programs in dozens of countries. The patient remote monitoring platform Show2Doc with ‘white label’ offer can become the

branded solution for MOH, governors and mayors to bring their own named App for their citizens and doctors to prevent personal contacts, perform remote health monitoring and create high-end treatment management.

In fact – we are bringing a complete ecosystem for remote care for chronic and COVID patients. Every citizen can be wired to his physician by Show2Doc – as an all-territory service for remote health monitoring and treatment correction. Any ill patient may be diagnosed at home by IDIS2GO – just to give it in hands of outpatient clinics.



— What are the most common use cases of the IDIS2GO diagnostic and monitoring system?

As I said before, healthcare providers use it in remote areas, for patients with chronic diseases, the elderly, pregnant women, and anyone who has difficulty reaching a clinic.  


Telehealth medical diagnostic system IDIS2GO is used in various environments: ambulance crews, outpatient clinics, rural health care centers, emergency and elderly care workers as well as military units, and production facilities.  IDIS2GO has become an effective solution for complete remote diagnosis, observation and monitoring of patients during the SARS-CoV-2 quarantine and post-vaccination measures.



— Can you add something in your solution or adjust it according the needs of the market?

As a digital health care provider SK-Telemed GmbH is able to adjust IT solutions for healthcare also upon their needs and requests. Our successful experience of creation and managing MIS, HIS, telehealth and telemedicine platforms give us a right to be an expert in this topic and support projects in every step of developing on cities, province, and state levels.


The epidemic will last for at least another 2 years, and government agencies should already be thinking not only about oxygen units and beds, but also about prevention and remote treatment of cardiac and endocrinological patients, taking care also of pregnant women and children.

First of all, our solutions help to save lives and we are happy being part of path that cares about people and give access to high quality diagnostics and treatment from any patient location.


]]> ]]> https://www.pressreleasepower.com/news/public-health/catherine-chuchylina-our-solutions-help-to-save Thu, 03 Jun 2021 12:43:11 +0600 <![CDATA[Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury]]> Angion Biomedica Corp and Vifor Pharma today announced completion of enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI). This indication is part of the ANG-3777 license agreement both parties signed in November 2020.

“CSA-AKI is a frequent complication of cardiac bypass surgery seen in about one third of patients and is associated with prolonged hospitalization, progressive kidney failure, and an increased risk of death,” commented Dr. John Neylan, Angion’s Senior Vice President and Chief Medical Officer. “Currently, there are no approved therapies to prevent this serious condition. This Phase 2 prevention trial was designed to generate data on ANG-3777 in CSA-AKI patients to help guide future development of ANG-3777 in a Phase 3 registration trial for CSA-AKI. We are planning to start the confirmatory trial early in 2022, subject to the results of this Phase 2 trial as well as discussions with the FDA and other relevant health authorities.”

Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma Group commented: “We are excited that enrollment in the AKI-002-15 Phase 2 trial has completed. This is an important milestone in a comprehensive clinical program to advance ANG-3777 as a potential treatment option to prevent acute kidney injury following cardiac surgery, an indication with a high unmet medical need. Together with our partner Angion, we now look forward to assessing the results from the trial.”



The fully enrolled Phase 2 trial is a randomized, multi-center, double-blind, placebo-controlled clinical trial with trial sites in the United States, Canada, Brazil, and Georgia. Patients at risk for CSA-AKI were randomized one-to-one to receive four intravenous doses of 2.0 mg/kg of ANG-3777 or placebo over four days. The first dose was given within four hours of the completion of surgery with subsequent doses given at 24-hour intervals. The primary endpoint is mean area under the curve of the percent increase in serum creatinine above baseline, starting from 24 hours after the end of cardiopulmonary bypass surgery through day six. 

An additional important endpoint is the occurrence of Major Adverse Kidney Events at 90 days (MAKE 90), which has previously been agreed by the FDA as a suitable primary endpoint for a registration trial in this indication. A MAKE 90 "event" is death, initiation of renal replacement therapy or a greater than 25% decline in eGFR present 90 days after the surgery. The AKI-002-15 Phase 2 trial was designed as a signal-finding trial with the strategic objective to obtain sufficient evidence of efficacy of ANG-3777 to appropriately power and evaluate potential enrichment strategies for a Phase 3 registration trial.

About ANG-3777
ANG-3777 is an investigational small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the c-Met cascade of pathways involved in tissue and organ repair. ANG-3777 has demonstrated a substantially longer half-life than HGF and Angion believes ANG-3777 has the potential to be a first-in-class therapeutic addressing acute organ injury. 

Enrollment is complete in a Phase 3 registration trial in transplant-associated acute kidney injury, also known as delayed graft function, a Phase 2 exploratory trial in cardiac-surgery associated acute kidney injury, and a Phase 2 exploratory trial in patients with acute lung injury associated with COVID-19 pneumonia. In November 2020, Vifor Pharma and Angion signed a license agreement for global rights excluding Greater China to commercialize ANG-3777 in renal indications with up to $1.925 billion in development, commercial, and sales milestones plus royalties on net sales of up to 40%. Sinovant Sciences and Angion signed a development and licensing agreement for ANG-3777 in Greater China in 2018.

About Angion
Angion is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic currently being evaluating in a Phase 3 registration trial for delayed graft function in patients undergoing deceased donor kidney transplantation, a Phase 2 trial in cardiac-surgery associated acute kidney injury, and a Phase 2 trial in patients with COVID-19 related pneumonia at high risk for acute respiratory distress syndrome. Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor. For more information, please visit www.angion.com.

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceutical company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.

Forward Looking Statements

Statements contained in this press release regarding matters that may occur in the future are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements in this press release regarding Angion’s expectations regarding the potential safety and efficacy of ANG-3777, the potential results and outcomes of the AKI-002-15 study, and other studies involving ANG-3777 or other product candidates, the timing of the commencement of future clinical trials and the timing of availability of and Angion’s disclosure of topline data from such studies. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. 

In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: Angion’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of ANG-3777 and its other product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete clinical trials; the results of preclinical studies may not be predictive of future results; the unpredictability of the regulatory process; regulatory developments in the United States, and other foreign countries; the costs of clinical trials may exceed expectations; the Company’s ability to raise additional capital; the effects of COVID-19 on the Company’s clinical programs and business operations. 

For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 30, 2021, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law. 


Contact and further information:

For Angion:
Daniel Ferry
LifeSci Advisors
617-430-7576
daniel@lifesciadvisors.com

Vifor Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73 
media@viforpharma.com

Vifor Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com

Source URL - https://www.einpresswire.com/article/539742288/angion-and-vifor-pharma-announce-completion-of-enrollment-in-phase-2-study-of-ang-3777-for-cardiac-surgery-associated-acute-kidney-injury


]]> ]]> https://www.pressreleasepower.com/news/public-health/angion-and-vifor-pharma-announce-completion-of Thu, 29 Apr 2021 12:34:48 +0600 <![CDATA[Anjum Khanna – What is Muscular Atrophy]]> According to Anjum Khanna, Due to lack of physical activity, muscles waste away. At the point when a sickness or injury makes it troublesome or inconceivable for you to move an arm or leg, the absence of versatility can bring about muscle atrophy. Over the long haul, without customary development, your arm or leg can begin to seem more modest yet not more limited than the one you’re ready to move. 

Now and again, muscle atrophy can be turned around with an appropriate eating routine, work out, or exercise based recuperation. Also you can get more information on Anjum Khanna Blogs.

Symptoms of Muscle Atrophy

Why it happens because,

  • One of your arms or legs is noticeably smaller than the other.
  • You’re experiencing marked weakness in one limb.
  • You’ve been physically inactive for a very long time.

Call your Doctor to plan a total clinical treatment in the event that you trust you may have muscle atrophy or in the event that you can’t move typically. You may have an undiscovered condition that requires treatment.

Causes of Muscle Atrophy 

  • lack of physical activity for an extended period of time
  • aging
  • alcohol-associated myopathy, a pain and weakness in muscles due to excessive drinking over long periods of time
  • burns
  • injuries, such as a torn rotator cuff or broken bones
  • malnutrition
  • spinal cord or peripheral nerve injuries
  • stroke
  • long-term corticosteroid therapy

Ayurvedic Treatment for Muscle Atrophy

Anjum khanna ayurvedic care provides best ayurvedic treatment for Muscular Atrophy. Our Ayurvedic Management Team of Muscular Atrophy treatment will include affirming legitimate sustenance to the muscle tissue and to exact the fire segment related with the solid tissue of the body guaranteeing fitting nourishment to the entire body and to the muscles specifically in this manner keeping a decent scope of development of the multitude of joints of the body and reinforcing them. Ayurvedic Management of comprehensive treatment, utilizing herbals, diet and yogic help delineate solid proof of extensive advantage for youngsters and grown-ups with neuro-strong inability and solid dystrophies. Ayurvedic spices defer the cycle of pulverization of muscles by improving Agni, which is a key factor needed to synthesize cellular protein.

Anjum Khanna ayurvedic therapies include udvartana with steam, abhyanga and swedam, dhanyamla dhara, nasya karma, karna pooranam, snehapanam which is followed by Virechanam, shiro vasti, shiro dhara, sarvanga dhara (Pizhichil), shiro pichu, thalam, navarakizhi, vasti (Mustadi raja yapana vasti), rasayana chikitsa. It also includes mud therapy and enema. Other therapies include meditation, pranayama, yoga, exercise, diet and lifestyle modification. 

Gentle yoga asanas and breathing exercises helps in strengthening the muscles, spine and helps to have good neuro-muscular fitness.

  • Tad asana
  • Padahastasana
  • Trikonasana
  • Vakrasana
  • Relaxation
  • Paschimottanasana
  • Vakrasana
  • Shashankasana
  • Pawanmuktasana
  • Ardha Shalabhasana

Pranayamas:

  • Left nostril breathing
  • Right nostril breathing
  • Sitali or Sitkari

About Anjum Khanna

Anjum Khanna The specialist of Ayurveda” he completed his MD in Ayurveda at Gujarat Ayurved University (Jamnagar) and completed his Bachelor of Ayurvedic Medicine and Surgery at Indian Institute of Ayurvedic Medicine & Research (IIAMR), Bangalore, Karnataka, India. His Clinic is situated in Srinagar because srinagar is the nature’s beauty and this place is suitable for ayurvedic treatment. In Our Clinic many patients come here across the world.



 



]]> ]]> https://www.pressreleasepower.com/news/public-health/anjum-khanna-what-is-muscular-atrophy Tue, 05 Jan 2021 09:04:39 +0600 <![CDATA[MemoryCare.com Names the Best Facilities for Senior Memory Care in Des Moines, IA]]> MemoryCare.com, a comprehensive resource for caregivers and older adults living with memory impairment, has announced the Best Memory Care Facilities in Des Moines, Iowa. The guide identifies 12 memory care communities based on location, access to experts, facility features and amenities.

According to the Alzheimer’s Association, 5.6 million people age 65 and older are living with Alzheimer's dementia. In Des Moines, the number of senior deaths related to Alzheimer’s increased by 30 percent between 2013 and 2017. Memory care facilities offer activities and therapies to help delay or halt cognitive decline. They also give family members and caregivers peace of mind by providing a safe environment for loved ones.

“There’s a high demand for quality memory care all across our nation; specifically, in cities like Des Moines, which experienced a rapid increase in Alzheimer’s related deaths,” says Joyce Collins. “MemoryCare.com provides free resources to help families find the best facilities.”

Through hours of research and an intensive selection process, MemoryCare.com was designed to help caregivers find effective solutions for their loved ones. The website not only highlights the best facilities in the city, it also shares information about cost, reviews from residents, type of care offered, and more. For a detailed listing of the Best Memory Care Facilities in Des Moines, IA, please visit https://www.memorycare.com/des-moines-ia-facilities/

2020 Best Memory Care Facilities in Des Moines, IA (in alphabetical order)

3801 Grand
Phone Number: (515) 255-3499
Address: 3801 Grand Ave., Des Moines, IA 50312
Website: 3801grand.com/

Arlington Place of Red Oak
Phone Number: (712) 623-1999
Address: 800 East Ratliff Ave., Red Oak, IA 51566
Website: arlingtonplaceretirement.com/

Courtyard Estates – Pleasant Hill
Phone Number: (515) 285-9108
Address: 6132 NE. 12th Ave., Pleasant Hill, IA 50327
Website: ourtyard-estates.net/

Edencrest at Beaverdale
Phone Number: (515) 305-2844
Address: 3410 Beaver Ave., Des Moines, IA 50310
Website: edencrestliving.com/

Glenwood Place
Phone Number: (641) 752-8410
Address: 2907 South 6th St., Marshalltown, IA 50158
Website: glenwood-place.com/

Journey Senior Services
Phone Number: (712) 775-2313
Address: 17504 Mahogany, Carroll, IA 51401
Website: journeyseniorservices.com/

Parker Place
Phone Number: (319) 346-9771
Address: 707 Hwy. 57, Parkersburg, IA 50665
Website: parkerplaceretirement.com/

Perry Lutheran Home Willis Avenue Campus
Phone Number: (515) 465-5342
Address: 2323 Willis Ave., Perry, IA 50220
Website: perrylutheranhome.org/

Prairie Hills at Ottumwa
Phone Number: (641) 684-1871
Address: 173 E. Rochester, Ottumwa, IA 52501
Website: prairiehillsottumwa.com/

Sunnybrook of Fairfield
Phone Number: (641) 469-5778
Address: 3000 W. Madison Ave. Suite 500, Fairfield, IA 52556
Website: sunnybrookfairfield.com/

The Bridges at Ankeny
Phone Number: (515) 963-9815
Address: 3510 NW. Abilene Rd., Ankeny, IA 50023
Website: thebridgesankeny.com/

Vintage Hills of Indianola
Phone Number: (515) 961-1924
Address: 604 E Hillcrest Ave., Indianola, IA 50125
Website: vintagehillssenior.com/

ABOUT MEMORYCARE.COM
MemoryCare.com provides tools and resources to help adults living with memory impairment and their families. The online guide uses data-driven research and expert evaluations to identify the best facilities across the nation. The MemoryCare.com team includes medical and eldercare professionals as well as the board of directors. For more information, visit https://www.memorycare.com/.

Source:     http://www.prweb.com/releases/memorycare_com_names_the_best_facilities_for_senior_memory_care_in_des_moines_ia/prweb17076993.htm
]]> ]]> https://www.pressreleasepower.com/news/public-health/memorycarecom-names-the-best-facilities-for-senior-memory-care-in-des-moines-ia Sat, 23 May 2020 13:15:24 +0600 <![CDATA[Testing Initiative Planned at Juvenile Facility in Concord Following Staff Report of COVID-19 Infection]]> Upon the advice of the Cabarrus Health Alliance, (Cabarrus County's local health department), all juveniles at Stonewall Jackson Youth Development Center will undergo COVID-19 testing over the next few days after a staff member there tested positive for the coronavirus.

A staff member at Stonewall Jackson Youth Development Center has self-reported testing positive for coronavirus, also known as COVID-19. Positive test results were reported to the facility by the employee on May 15, 2020.

The Juvenile Justice employee has been off the job since May 10, following notification to facility management of a potential exposure to the coronavirus. The individual became symptomatic on May 13, when the COVID-19 test swab was taken and sent to a lab for processing.

The Juvenile Justice section is following guidelines from the CDC, N.C. Department of Health and Human Services and local health department in conducting contact tracing and notification procedures, as well as quarantine and cleaning protocols. All staff members believed to have had close contact with the individual will undergo quarantine and testing.

When we learned of our staff member?s potential exposure earlier this week, we placed on quarantine two juvenile living units where potential contact could have occurred as a standard precaution,? said Peter Brown, director of Stonewall Jackson YDC. ?We are monitoring the children on these units twice a day for fever and/or symptoms. Though to date no juveniles have displayed any symptoms associated with COVID-19, we are taking the step of testing all children out of an abundance of caution.?

Staff members at Stonewall Jackson YDC have also been offered testing through the local health department, or through an initiative announced earlier this week for free, confidential and convenient testing to all employees of the Adult Correction and Juvenile Justice.

To date, there have been no confirmed COVID-19 infections of children in North Carolina's Juvenile Justice facilities. It is important to note that social distancing is possible within juvenile detention centers and youth development centers. Juvenile detention centers, and individual living units within youth development centers, are comprised of a common area used for meals and recreation, along with individual rooms for each juvenile.

?We appreciate the quick and proactive assistance of the Cabarrus Health Alliance in this testing initiative at Stonewall Jackson YDC,? said William Lassiter, deputy secretary for Juvenile Justice. ?Through the implementation of operational changes during this pandemic, Juvenile Justice has been following strict policies and procedures to reduce the opportunities for the potential spread of the virus in all our facilities, and to protect the health and well-being of our staff and the children who are in our care.?

To date, some of these operational changes include:

Suspending visitation and volunteer activities at all juvenile justice facilities, until conditions are deemed safe. All non-essential volunteers, contractors, and vendors are prohibited from entry. Contractors/staff undergo screening procedures prior to entry.
Placing all juvenile detention center/crisis and assessment center admissions in medical room confinement for up to 14 days or until cleared by a medical provider to join the general population.
Screening all juveniles prior to transportation. If a juvenile is feverish or has a respiratory illness, the juvenile shall not be transported.
Placing into medical room confinement all juveniles in secure custody with symptoms while investigating the source of their medical issues. This is being done to prevent the spread of coronavirus if it emerges in the population.
Rescheduling all non-critical off-site medical appointments.
Presenting specific educational information and training at facilities for staff members and youths around COVID-19 safety precautions including washing of hands, social distancing, information about how the coronavirus is transmitted and wearing of face masks.
Posting informational literature in all facilities to stress the washing of hands and other preventive measures juveniles, staff and visitors can take to reduce the spread of diseases.
Decreasing the number of youths in detention through the utilization of electronic monitoring.
Suspending home visits for youth committed to a youth development center and deferring the requirement that a juvenile complete all pre? release home visits before being released from a youth development center.
Increasing the number of phone calls permitted between juveniles and their families.
Increasing the use of telehealth services, to include the provision of mental health services.
Handling necessary court hearings via videoconference.

Source :       https://www.pressreleasepoint.com/testing-initiative-planned-juvenile-facility-concord-following-staff-report-covid-19-infection
]]> ]]> https://www.pressreleasepower.com/news/public-health/testing-initiative-planned-at-juvenile-facility-in-concord-following-staff-report-of-covid-19-infection Mon, 18 May 2020 09:01:32 +0600